Sepsis is a complex clinical syndrome associated with high morbidity and mortality and organ dysfunction, most notably acute kidney injury. Early recognition determines crucial clinical decisions for septic individuals. This rapid diagnosis depends on the accuracy of biomarkers in the context of coexisting renal dysfunction. In this context, the value of presepsin has been investigated and challenged for a decade, with no definitive answers. This scoping review aims to evaluate the existing evidence regarding the accuracy of presepsin as a diagnostic and prognostic biomarker for sepsis-associated acute kidney injury (SA-AKI). We obtained 130 articles by searching for references in databases (PubMed/Medline, Web of Science, Embase, and Scopus) following the PRISMA-ScR guidelines. Sequential selection by three independent readers resulted in nine references retained for full analysis. Presepsin demonstrated good diagnostic and prognostic accuracy in patients with AKI, based on observations in small patient groups; however, it requires specific cutoff values, whose determination depends on new controlled and randomized studies.
Moura et al. (Wed,) studied this question.